NuraLogix Unveils Multi-Year Cardiovascular Risk Index         

AI-powered predictive insights expand the frontiers of proactive heart-health monitoring — up to 20 years into the future

Toronto, ON – [Oct 20, 2025] – NuraLogix, a pioneer in contactless health insight technology, announced its latest research capability today, a multi-year cardiovascular disease (CVD) risk model, a breakthrough capability that estimates an individual’s long-term likelihood of developing cardiovascular disease over customizable timeframes ranging from 1 to 20 years. CVD risk refers to the likelihood of developing conditions such as heart attack, stroke, or peripheral artery disease, and serves as a key indicator for understanding and supporting long-term heart health.

Building on its existing 10-year cardiovascular model, the new multi-year version offers greater flexibility and long-range forecast, enabling health technology partners, wellness platforms, and research organizations to better understand population-level risk trajectories and explore the long-term impacts of wellness and lifestyle factors, all through a contactless, camera-based experience.

Cardiovascular disease remains the #1 cause of death globally, responsible for nearly 18 million lives each year.  According to the World Health Organization, over 80% of these deaths are due to heart attacks and strokes, with one-third occurring prematurely in people under 70.[1] While most discussions in healthcare focus on treatment, the true frontier lies in early detection and continuous risk awareness.

The new NuraLogix model was trained on data from over 100,000 individuals across diverse populations, creating a more globally representative dataset than previous U.S.-focused versions. Unlike traditional regression-based approaches, it uses advanced machine-learning techniques to adaptively capture complex physiological patterns applicable across regions and demographics.

“Cardiovascular disease doesn’t develop overnight,” said Dr. Keith Thompson, Chief Medical Officer at NuraLogix. “By extending our predictive horizon to 20 years, this capability provides valuable insight into how lifestyle and wellness factors could influence long-term cardiovascular health. It empowers users and organizations to make data-informed decisions that support prevention and early intervention. “

For more information about the Anura® Cardiovascular long-term outlook and NuraLogix’s suite of Ai-powered health solutions, visit www.nuralogix.ai

About Affective AI™

Affective AI is the intersection between Affective Computing and Artificial Intelligence. It is the ability to recognize, measure, predict and simulate human affects that take the form of physiological and psychological states using AI trained models.

About Nuralogix

Nuralogix is a pioneer in the development of Affective Ai™ and the creator of groundbreaking contactless blood pressure measurement technology. The company’s patented cloud based Affective Ai™ Platform- DeepAffex™ can measure over 100 health and wellness parameters using a conventional video camera and its patented Transdermal Optical Imaging (TOI™) technique to extract facial blood flow information from the human face. This is demonstrated in the most widely recognized of the contactless health monitoring Anura® app.

1 https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1